BEST UNLIMITED TURBO LONG CERTIFICATE - GALAPAGOS

BEST UNLIMITED TURBO LONG CERTIFICATE - GALAPAGOS Stock

FY58S

DE000SW8RLX7

Market Closed - Euronext Paris 12:30:00 2024-05-31 pm EDT
8.62 ^EUR	+5.95%

1 month

-10.74%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart GALAPAGOS NV

Chart BEST UNLIMITED TURBO LONG CERTIFICATE - GALAPAGOS

Latest news about GALAPAGOS NV

Galapagos, Adaptimmune to Jointly Develop Head, Neck Cancer Treatment	May. 31	MT
Galapagos, Adaptimmune Therapeutics Team Up to Evaluate Head and Neck Cancer Drug	May. 31	MT
Galapagos : Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune’s TCR T cell therapy candidate, uza cel, in head & neck cancer and potential future so	May. 31	PU
Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune’s TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications	May. 30	GL

More news

Quotes 5-day view

Date	Price	Change
24-05-31	8.804	+8.21%
24-05-30	8.136	+3.27%
24-05-29	7.878	-2.91%
24-05-28	8.114	-3.26%
24-05-27	8.387	+1.70%

Real-time Euronext Paris

Last update May 31, 2024 at 12:30 pm EDT

More quotes

Static data

Product type	Certificat Turbo
Buy / Sell	CALL
Underlying	GALAPAGOS NV
Issuer	Société Générale
	FY58S
ISIN	DE000SW8RLX7
Date issued	2024-04-09
Strike	17.69 €
Maturity	Unlimited
Parity	1 : 1
Emission price	12.07 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	12.66 €
Lowest since issue	7.843 €

Company Profile

Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing innovative medicines. The company is committed to improving patients' lives worldwide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan.

Sector

More about the company

Ratings for Galapagos NV

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Consensus: Galapagos NV

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

25.74 EUR

Average target price

37.03 EUR

Spread / Average Target

+43.86%

Consensus